Search Results - "PETRENKO, Oleksi"

Refine Results
  1. 1

    KRAS drives immune evasion in a genetic model of pancreatic cancer by Ischenko, Irene, D’Amico, Stephen, Rao, Manisha, Li, Jinyu, Hayman, Michael J., Powers, Scott, Petrenko, Oleksi, Reich, Nancy C.

    Published in Nature communications (05-03-2021)
    “…Immune evasion is a hallmark of KRAS-driven cancers, but the underlying causes remain unresolved. Here, we use a mouse model of pancreatic ductal…”
    Get full text
    Journal Article
  2. 2

    STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer by D'Amico, Stephen, Kirillov, Varvara, Petrenko, Oleksi, Reich, Nancy C

    Published in eLife (04-04-2024)
    “…Oncogenic mutations in KRAS are among the most common in cancer. Classical models suggest that loss of epithelial characteristics and the acquisition of…”
    Get full text
    Journal Article
  3. 3

    Direct reprogramming by oncogenic Ras and Myc by Ischenko, Irene, Zhi, Jizu, Moll, Ute M., Nemajerova, Alice, Petrenko, Oleksi

    “…Genetically or epigenetically defined reprogramming is a hallmark of cancer cells. However, a causal association between genome reprogramming and cancer has…”
    Get full text
    Journal Article
  4. 4

    The MDM2-p53 Interaction by Moll, Ute M, Petrenko, Oleksi

    Published in Molecular cancer research (01-12-2003)
    “…Activation of the p53 protein protects the organism against the propagation of cells that carry damaged DNA with potentially oncogenic mutations. MDM2, a…”
    Get full text
    Journal Article
  5. 5

    Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas by Ischenko, Irene, Petrenko, Oleksi, Hayman, Michael J.

    “…Pancreatic cancer is one of the deadliest human malignancies. A striking feature of pancreatic cancer is that activating Kras mutations are found in ∼90% of…”
    Get full text
    Journal Article
  6. 6

    Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer by Sivaram, Nithya, McLaughlin, Patrick A, Han, Han V, Petrenko, Oleksi, Jiang, Ya-Ping, Ballou, Lisa M, Pham, Kien, Liu, Chen, van der Velden, Adrianus W.M, Lin, Richard Z

    Published in The Journal of clinical investigation (01-08-2019)
    “…The presence of tumor-infiltrating T cells is associated with favorable patient outcomes, yet most pancreatic cancers are immunologically silent and resistant…”
    Get full text
    Journal Article
  7. 7

    A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells by Ischenko, Irene, Petrenko, Oleksi, Hayman, Michael J

    Published in Oncotarget (30-06-2015)
    “…Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive, metastatic disease with limited treatment options. Factors contributing to the metastatic…”
    Get full text
    Journal Article
  8. 8

    p53 Has a Direct Apoptogenic Role at the Mitochondria by Mihara, Motohiro, Erster, Susan, Zaika, Alexander, Petrenko, Oleksi, Chittenden, Thomas, Pancoska, Petr, Moll, Ute M.

    Published in Molecular cell (01-03-2003)
    “…p53 induces apoptosis by target gene regulation and transcription-independent signaling. However, a mechanism for the latter was unknown. We recently reported…”
    Get full text
    Journal Article
  9. 9

    IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3 by Petrenko, Oleksi, Li, Jinyu, Cimica, Velasco, Mena-Taboada, Patricio, Shin, Ha Youn, D'Amico, Stephen, Reich, Nancy C

    Published in PloS one (02-03-2021)
    “…The inflammatory cytokine IL-6 is known to play a causal role in the promotion of cancer, although the underlying mechanisms remain to be completely…”
    Get full text
    Journal Article
  10. 10

    In Vivo Mitochondrial p53 Translocation Triggers a Rapid First Wave of Cell Death in Response to DNA Damage That Can Precede p53 Target Gene Activation by Erster, Susan, Mihara, Motohiro, Kim, Roger H., Petrenko, Oleksi, Moll, Ute M.

    Published in Molecular and Cellular Biology (01-08-2004)
    “…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
    Get full text
    Journal Article
  11. 11

    ΔNp73 Facilitates Cell Immortalization and Cooperates with Oncogenic Ras in Cellular Transformation In Vivo by Petrenko, Oleksi, Zaika, Alexander, Moll, Ute M.

    Published in Molecular and Cellular Biology (01-08-2003)
    “…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
    Get full text
    Journal Article
  12. 12

    Mitochondrially targeted p53 has tumor suppressor activities in vivo by TALOS, Flaminia, PETRENKO, Oleksi, MENA, Patricio, MOLL, Ute M

    Published in Cancer research (Chicago, Ill.) (01-11-2005)
    “…Complex proapoptotic functions are essential for the tumor suppressor activity of p53. We recently described a novel transcription-independent mechanism that…”
    Get full text
    Journal Article
  13. 13

    A Functional Screen for Myc-Responsive Genes Reveals Serine Hydroxymethyltransferase, a Major Source of the One-Carbon Unit for Cell Metabolism by Nikiforov, Mikhail A., Chandriani, Sanjay, O'Connell, Brenda, Petrenko, Oleksi, Kotenko, Iulia, Beavis, Andrew, Sedivy, John M., Cole, Michael D.

    Published in Molecular and Cellular Biology (01-08-2002)
    “…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
    Get full text
    Journal Article
  14. 14

    Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis by Nemajerova, Alice, Palacios, Gustavo, Nowak, Norma J, Matsui, Sei-Ichi, Petrenko, Oleksi

    Published in PloS one (11-11-2009)
    “…Transcriptional silencing of the p73 gene through methylation has been demonstrated in human leukemias and lymphomas. However, the role of p73 in the malignant…”
    Get full text
    Journal Article
  15. 15

    Macrophage Migration Inhibitory Factor Coordinates DNA Damage Response with the Proteasomal Control of the Cell Cycle by Nemajerova, Alice, Moll, Ute M., Petrenko, Oleksi, Fingerle-Rowson, Günter

    Published in Cell cycle (Georgetown, Tex.) (02-05-2007)
    “…Proper repair of DNA damage is critical for protecting genomic stability, cellular viability and suppression of tumorigenesis. Both p53-dependent and…”
    Get full text
    Journal Article
  16. 16

    MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models by Fingerle-Rowson, Günter, Petrenko, Oleksi

    Published in Cell division (19-07-2007)
    “…Macrophage migration inhibitory factor (MIF) is a ubiquitously expressed pro-inflammatory mediator that has also been implicated in the process of oncogenic…”
    Get full text
    Journal Article
  17. 17

    E2F1 plays a direct role in Rb stabilization and p53-independent tumor suppression by Palacios, Gustavo, Talos, Flaminia, Nemajerova, Alice, Moll, Ute M, Petrenko, Oleksi

    Published in Cell cycle (Georgetown, Tex.) (15-06-2008)
    “…To better understand the role of E2F1 in tumor formation, we analyzed spontaneous tumorigenesis in p53-/-E2F1+/+ and p53-/-E2F1-/- mice. We show that the…”
    Get full text
    Journal Article
  18. 18

    Macrophage Migration Inhibitory Factor Deficiency Is Associated with Altered Cell Growth and Reduced Susceptibility to Ras-mediated Transformation by Petrenko, O, Fingerle-Rowson, G, Peng, T, Mitchell, R A, Metz, C N

    Published in The Journal of biological chemistry (28-03-2003)
    “…Macrophage migration inhibitory factor (MIF) has been shown to functionally inactivate the p53 tumor suppressor and to inhibit p53-responsive gene expression…”
    Get full text
    Journal Article
  19. 19

    Scaffolding protein Gab2 mediates fibroblast transformation by the SEA tyrosine kinase by ISCHENKO, Irene, PETRENKO, Oleksi, GU, Haihua, HAYMAN, Michael J

    Published in Oncogene (25-09-2003)
    “…Transformation of fibroblasts by V-SEA involves activation of the ERK and phosphatidylinositol 3-kinase (PI3K) pathways. Effector proteins that are key…”
    Get full text
    Journal Article
  20. 20

    STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer by D'Amico, Stephen, Kirillov, Varvara, Petrenko, Oleksi, Reich, Nancy C

    Published in eLife (04-04-2024)
    “…Oncogenic mutations in KRAS are among the most common in cancer. Classical models suggest that loss of epithelial characteristics and the acquisition of…”
    Get full text
    Journal Article